Compare Danaher Corporation (DHR) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Banco Santander SA — how do they compare? Danaher Corporation trades at $204.42 (market cap $145.83B), while Banco Santander SA trades at $14.85 (market cap $211.63B). The key difference: Banco Santander SA is the larger of the two by market cap, and Banco Santander SA pays the higher dividend (1.89%). Which is the better fit depends on your goals.
| DHR | SAN | |
|---|---|---|
Market Cap | $145.83B | $211.63B |
Sector | Health | Financials |
52-Week High | $242.05 | $14.71 |
52-Week Low | $161.91 | $9.37 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Banco Santander (SAN) trades at $14.69, showing minimal daily movement with a slight decline of 0.07%. The stock maintains a bullish technical signal supported by moving averages, while oscillators indicate neutral momentum. Fundamentally, the company reported strong profitability with a 26.25% net income margin and record quarterly profits in Q2 2026. Recent developments include Federal Reserve approval for the $12 billion Webster Bank acquisition, positioning Santander for strategic expansion.
The outlook remains positive with analyst consensus favoring Buy ratings (64%) and the company achieving Spain's most valuable listed company status. Key risks include volatile cash flow trends with negative operating cash flow in 2024-2025 and restructuring charges from recent acquisitions. Revenue growth is projected to reach $61.9B in 2026, supporting continued investor confidence despite near-term earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
